Navigation Links
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting
Date:12/13/2011

SAN DIEGO, California, December 13, 2011 /PRNewswire/ --

-- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform --

Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations", the results demonstrated Pieris' PRS-080's ability to increase the serum iron levels in preclinical models by binding the hepcidin target with high affinity and specificity, while offering the flexibility of a tunable pharmacokinetic (PK) and pharmacodynamic (PD) profile.

"These studies in multiple preclinical species and models demonstrate the high level of control offered by the Anticalin approach in combination with PEGylation to create 'fit for purpose' PK/PD profiles that can match specific target biology across different patient populations," stated Laurent Audoly, Ph.D., Chief Scientific Officer of Pieris.  "In particular, the clear relationship between PEG formats and the resulting PK/PD profile for several PRS-080 variants tested in animal models provides an extremely encouraging basis for a rapid advance toward the clinic and creates a portfolio of molecules adapted for different hepcidin-dependent diseases."

The presentation at ASH included several in vivo animal studies of PRS-080's sub-nanomolar potency in binding hepcidin, which is a small peptide that plays a pivotal role in the regulation of iron levels in the blood.  In addition, Pieris researchers documented reliable drug half-life levels dependent on the size of the PEGylated compound.  In several preclinical models, a single dose of four different formulations of PRS-080 showed clear cor
'/>"/>

SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Therapeutics to 2020 - Broadened Diagnostic ... Drive Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 ...
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 84 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
... European Association for the Study of ... Diabetes Annual Meeting, ... Annual Meeting of the European Association for the Study,of Diabetes demonstrate ... cardiovascular disease in patients with type 2,diabetes. ACTOS is an oral ...
... Therapy, ALEXANDRIA, La., Sept. 18 Life ... NJ, an emerging provider of,groundbreaking medical devices for ... ThermoSuit(R) System has been granted European CE,Mark (Conformite ... indicated, e.g., to induce hypothermia in patients to,preserve ...
Cached Medicine Technology:ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 2ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 3Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
(Date:8/28/2014)... August 28, 2014 Millennium Treatment ... throughout September. This month will be a celebration ... mental health services. Along with other treatment facilities ... helping to spread the word about this national ... honoring the work of treatment and recovery professionals, ...
(Date:8/28/2014)... Nashville, TN (PRWEB) August 28, 2014 ... the insurance industry on the Internet will now have ... Quotes Pros company. In one click this year, some ... presented at http://quotespros.com/life-insurance.html . , The promoted ... the Quotes Pros finder tool represent popular policies. The ...
(Date:8/28/2014)... ABC television stars will join forces this Labor ... Telethon airing Sunday, Aug. 31, 9/8c on ABC television ... awareness to help save and improve the lives of ... tuning into the 2014 telethon to benefit the Muscular ... some of the network’s leading stars, including Alyssa Milano ...
(Date:8/28/2014)... Pittsburgh, PA (PRWEB) August 28, 2014 ... Ready Nutrition announced today a regional partnership designed ... and goal planning for competitive young athletes, scholastic ... , “Our partnership’s Strong Body & Mind Initiative ... that addresses both the physical and mental dynamics ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... major league pitcher , FRIDAY, Oct. 30 (HealthDay News) -- ... than a second, it curves and then drops, baffling the ... correctly, is one of baseball,s most daunting pitches. For more ... sworn that the ball seems to have a life of ...
... Partnership to scale ... ... for AIDS Relief (PEPFAR), the largest commitment ever by any nation to combat a single ... Ambassador Eric Goosby, U.S. Global AIDS Coordinator, who oversees implementation of PEPFAR , in ...
... Oct. 30 NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY ... antifungal activity in an established pre-clinical infected nail model ... at the 47th Annual Meeting of the Infectious Diseases ... tests both the penetration of the nail as well ...
... 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the ... INTUNIV (guanfacine) Extended Release Tablets, at a major psychiatric ... study was to assess the change from baseline on ... Long Form (CPRS-R:L) in patients ages 6 to ...
... ,Charles Drew University has ... the university,s long-term, UCLA partnership aimed at reducing the risk of ... The National Institutes of Health, the National Cancer Institute and the ... Cancer Center Partnership. An additional $4.5 million was allocated to ...
... ... Kentucky felt his heart racing after playing Millsaps College homecoming game on Saturday, October 24, ... Jackson, MS (Vocus) ... his heart racing after playing Millsaps College homecoming game on Saturday, October 24, 2009. , ...
Cached Medicine News:Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 2Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 3Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 2Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 3Health News:NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 4Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 2Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 3Health News:Charles Drew University awarded $9.8 million 2Health News:College Middle Line Backer Treated for Wolff Parkinson White Syndrome at Baptist Cardiovascular Services 2Health News:College Middle Line Backer Treated for Wolff Parkinson White Syndrome at Baptist Cardiovascular Services 3
... St. Jude Medical offers the world's ... Pacel bipolar pacing catheters are available in ... a broad range of curve choices and ... Pacing Catheter is indicated for use in ...
Automated slide maker and stainer...
... treadmill has streamlined design, "whisper ... brushless DC motor and direct ... system that operates on standard ... smooth operation, remarkably low motor ...
... Series 2000 Treadmill is advanced in ... The extra-long, 60-inch treadmill surface provides ... patients. The Series 2000 Treadmill ... accommodate severely debilitated patients. Its extremely ...
Medicine Products: